TNFRSF11A and alkaptonuria: That same study revealed increased levels of the receptor activator of nuclear factor kappa-B (RANK) and reduced levels of osteoprotegerin (OPG), suggesting that osteoclast activation resulting from these changes contributes to bone loss in patients with alkaptonuria [36].